Malaria and dengue in Hodeidah city, Yemen: High proportion of febrile outpatients with dengue or malaria, but low proportion co-infected

Rashad Abdul-Ghani1,2,*, Mohammed A. K. Mahdy1,2, Sameer Alkubati3, Abdullah A. Al-Mikhlafy4, Abdullah Alhariri5, Mrinalini Das6, Kapilkumar Dave7, Julita Gil-Cuesta8

1 Department of Medical Parasitology, Faculty of Medicine and Health Sciences, Sana’a University, Sana’a, Yemen, 2 Tropical Disease Research Center, Faculty of Medicine and Health Sciences, University of Science and Technology, Sana’a, Yemen, 3 Department of Nursing, Faculty of Medicine and Health Sciences, Hodeidah University, Hodeidah, Yemen, 4 Department of Community Medicine, Faculty of Medicine and Health Sciences, University of Science and Technology, Sana’a, Yemen, 5 Preventive Medicine Unit, General Military Hospital, Hodeidah, Yemen, 6 Doctors without Borders, New Delhi, India, 7 Society for Education Welfare and Action—Rural, Jhagadia, India, 8 LuxOR Operational Research, Doctors without Borders, Brussels, Belgium

* rashadqb@yahoo.com

Abstract

Background

The emergence of dengue in malaria-endemic countries with limited diagnostic resources, such as Yemen, can be problematic because presumptive treatment of febrile cases as being malaria is a common practice. Co-infections with dengue and malaria are often overlooked and misdiagnosed as being a mono-infection because of clinical similarities. In Hodeidah city, Yemen, the capacity to conduct the diagnosis can be aggravated by the war context. To assess the magnitude of the problem, we determined the proportions of malaria, dengue and co-infection in relation to clinical characteristics among febrile outpatients.

Methods

This cross-sectional study included 355 febrile outpatients from Hodeidah city during the malaria transmission season (September 2018 –February 2019). Sociodemographic and clinical characteristics were collected using a pre-designed, structured questionnaire. Malaria was confirmed using microscopy and rapid diagnostic tests (RDTs), while dengue was confirmed using RDTs.

Results

Mono-infection proportions of 32.4% for falciparum malaria and 35.2% for dengue were found, where about two-thirds of dengue patients had a recent probable infection. However, co-infection with falciparum malaria and dengue was detected among 4.8% of cases. There was no statistically significant difference between having co-infection and mono-infection with malaria or dengue in relation to the sociodemographic characteristics. On the other
hand, the odds of co-infection were significantly lower than the odds of malaria among patients presenting with sweating (OR = 0.1, 95% CI: 0.05–0.45; \( p < 0.001 \)), while the odds of co-infection were 3.5 times significantly higher than the odds of dengue among patients presenting with vomiting (OR = 3.5, 95% CI: 1.20–10.04; \( p < 0.021 \)). However, there were no statistically significant differences between having co-infection and mono-infection (malaria or dengue) in relation to other clinical characteristics.

Conclusions
Mono-infection with malaria or dengue can be detected among about one-third of febrile outpatients in Hodeidah, while almost 5.0% of cases can be co-infected. Sociodemographic and clinical characteristics cannot easily distinguish malaria patients from dengue-infected or co-infected ones, reinforcing the necessity of laboratory confirmation and avoidance of treating febrile patients as being presumed malaria cases.

Background
Malaria and dengue are major mosquito-borne diseases in terms of morbidity and mortality in tropical and subtropical countries. Globally, malaria was estimated to affect 229 million people and cause 409,000 deaths in 2019 across 87 countries [1]. Meanwhile, the global burden of dengue has been increasing over the past 50 years, with an annual incidence estimate of about 350 million infections, and about half of the world’s population in endemic areas is at risk [2–4]. These diseases are often co-endemic and share similar clinical manifestations, with fever being the most common symptom [5]. Co-infections with these two diseases are often overlooked and misdiagnosed as being a mono-infection because of clinical similarities [6–8]. Malaria-dengue co-infection has been escalating after the increased reporting of dengue cases in malaria-endemic areas in various parts of the world since the first reported co-infected case in 2005 [9–14]. A systematic review reveals co-infection with both diseases in 20 countries in 2018 [5], ranging from 0.2% in Sierra Leone [15] to 23.0% among dengue-positive febrile patients in Pakistan [16].

In Yemen, over 165,000 confirmed malaria cases were reported by health facilities in 2019, predominantly caused by \( P. \) falciparum [1]. Concurrently, dengue cases have escalated; where several outbreaks caused by dengue virus (DENV) serotypes 2 and 3 have been reported between 2010 and 2012 [17–19]. DENV serotype 2 has been reported among about one-third of febrile patients with dengue-like illnesses in Hodeidah city, also called Al Hudaydah, in 2012 [19]. In Yemen, an increase of about six times in the number of suspected dengue cases was reported in 2016 compared with 2015 [20].

Diagnosis, care and control of malaria and dengue in Yemen have probably been affected by the unstable political situation and wars since 2012, where only half of the health facilities in the country were functional as of December 2018 [21]. A major problem is the lack of available diagnostic tests in Yemen that prompt physicians to assume that any acute febrile illness (AFI) is malaria and treat it as such, leading to unnecessary treatment of other AFIs. Inappropriate treatment of malaria-dengue co-infections can lead to severe complications or even death [14, 22–25], and unnecessary malaria treatment may contribute to the emergence and spread of drug resistance [26].
Misdiagnosis of febrile co-infections with shared clinical similarities is unavoidable in areas with overlapping endemicity. Although estimates of mono- and co-infections with malaria and dengue among febrile patients could be useful to clinicians, these are yet to be fully elucidated in Yemen. At the public health level, understanding the epidemiology of malaria and dengue, as mono- or co-infection, is essential for evidence-based approaches to appropriate control interventions. Therefore, we determined the proportions of malaria, dengue and malaria-dengue co-infection in relation to sociodemographic and clinical characteristics among febrile outpatients seeking healthcare and undergoing laboratory investigations for fever in the hospitals of Hodeidah city, west of Yemen—during malaria transmission season (November 2018 to April 2019).

Subjects and methods
Study design and setting
This hospital-based, cross-sectional study was conducted in accordance with STROBE guidelines [27] (S1 Checklist) in Hodeidah city in the period from November 2018 to April 2019. Hodeidah city is the capital of the governorate most afflicted by malaria in the country and comprises three districts: Al Mina, Al Hali and Al Hawak. It is located at the coordinates of 14° 48′08″N 42°57′04″E and is a main port on the Red Sea in western Yemen. It is the second most populated city after Sana’a—the capital of Yemen, with a total population of 1,093,000 in 2017 [28]. It is endemic for malaria and has witnessed several dengue outbreaks with a recently reported increase in the number of suspected dengue cases.

Study subjects
Febrile patients seeking healthcare in the outpatient departments of six tertiary care hospitals in Hodeidah were the target population of the study. Patients of any gender and age were included if referred for laboratory investigation of fever and having a directly observed axillary temperature of ≥37.5°C at presentation provided that they gave informed consent and were residents of Hodeidah city for at least six months before the study. We excluded patients who or whose guardians refused to give informed consent. We defined co-infection as an infection with i) malaria based on microscopy and/or RDT and ii) recent probable dengue based on RDT [non-structural antigen 1 (NS1) and/or IgM-positive] on the same day of taking blood samples. However, past infection with dengue was defined by the detection of anti-DENV IgG alone.

Sample size and sampling strategy
A minimum sample size of 273 was calculated using OpenEpi, version 3 (www.openepi.com) based on an expected co-infection proportion of 23% (the highest co-infection proportion found elsewhere [16]) at a confidence level of 95%, a precision of 5% and a design effect of 1.0. However, 355 patients were included from the three districts of Hodeidah city. Febrile patients referred to the laboratories of the hospitals of each district were invited to voluntarily participate in the study during the transmission season until the required sample size was attained.

Data and sample collection
Laboratory technicians were trained on the study recruitment, informed consent and data collection and supervised by a co-investigator of the study. Data on sociodemographic characteristics (gender, age, educational status, employment status, temperature and clinical characteristics (sweating, chills, headache, muscle pain, joint pain and vomiting) were
systematically collected using a paper-based, pre-designed structured questionnaire in Arabic (S1 Table). Drops of blood were collected onto slides by finger-prick for preparing blood films and rapid testing of malaria. Then, about 2–3 ml of whole blood samples were collected into pre-labeled plain test tubes and left to clot at room temperature. Sera were then separated by centrifugation at 3000 rpm for five minutes for dengue rapid testing.

**Laboratory investigations**

**Rapid diagnostic testing for malaria and dengue.** Blood drops were screened for malaria parasites using CareStart Malaria HRP2/pLDH (Pf/PAN) Combo RDTs to detect *P. falciparum* and non-falciparum species (AccessBio, New Jersey, USA). This test kit has been listed among the latest updated version of prequalified in vitro diagnostic products by the World Health Organization [29] and is one of the commonly used RDTs for malaria diagnosis in Yemen. Sera were tested for dengue through the detection of NS1 antigen and IgM/IgG antibodies with CareStart Dengue Combo RDTs. According to the guidelines of the US Centers for Disease Prevention and Control [30], the NS1 antigen is a useful tool for the diagnosis of acute dengue that can be detected in the serum as early as one day after the start of symptoms. Therefore, these RDTs can diagnose dengue at all clinical stages.

**Blood film microscopy.** Duplicate thick and thin blood films were prepared, stained with Giemsa for 20 minutes and examined under the oil-immersion lens of a light microscope by qualified microscopists according to standard procedures [31, 32].

**Data analysis**

Data were double-entered and validated using EpiData software, version 3.1 (EpiData Association, Odense, Denmark) and transferred for analysis using Stata, version 16 (College Station, Texas, USA). Continuous variables were summarized as mean and standard deviation (SD) for normally distributed data or median and interquartile range (IQR) for non-normally distributed data, while categorical variables were summarized as frequencies and proportions. Differences in the presence of clinical characteristics between co-infection and each type of mono-infection were analyzed using the chi-square or Fisher’s exact tests in bivariate analysis. Odds ratios (OR) for the difference between co-infection and each type of mono-infection were presented with their corresponding 95% confidence intervals (95% CI). Differences were considered statistically significant at *p*-values <0.05.

**Ethics statement**

Ethical approval for this study was obtained from the Research Ethics Committee of the Faculty of Medicine and Health Sciences, University of Science and Technology (UST), Sana’a, Yemen (EAC/UST136). Additional approval was obtained from the Ethics Advisory Group (EAG) of The Union, Paris, France (EAG number: 14/19). Written or, in some cases, oral informed consent was obtained in Arabic from patients or their parents/guardians for children younger than 15 years. Those who gave oral consent expressed their cautious concerns about signing or finger-printing any documents and preferred to consent orally with complete anonymity, instead. However, the Research Ethics Committee of the UST approved obtaining oral consent in such situations. In addition, because these participants had also concerns about recording their voices, data collectors put their signatures on the corresponding consent forms with the day and date of oral consent after ensuring that the participants fully understood the objectives of the study and giving them the telephone number of the Principal Investigator for any queries.
Results

Characteristics of the study population

At the end of the study, 355 febrile patients were tested. Table 1 shows that the majority of patients were males (63.1%) and aged between 20 and 40 years (54.0%), with a median age of 28.0 ± 21.0 years and a mean temperature of 38.8 ± 0.7 °C. Most patients were unemployed (49.1%) and living in households with more than four members (64.5%). It also shows that febrile patients had a mean temperature of 38.8 ± 0.7 °C, with headache being the most frequent clinical feature (91.5%) followed by joint pain (82.3%), chills (66.2%) and sweating.

Table 1. Sociodemographic and clinical characteristics of febrile patients attending the outpatient departments in hospitals of Hodeidah city, Yemen (2018–2019)*.

| Characteristic                  | n  | (%)   |
|--------------------------------|----|-------|
| Gender                         |    |       |
| Male                           | 224| (63.1)|
| Female                         | 131| (36.9)|
| Age (years) **                 |    |       |
| <20                            | 92 | (26.1)|
| 20–40                          | 190| (54.0)|
| >40                            | 70 | (19.9)|
| Median ± IQR: 28.0 ± 21.0      |    |       |
| District **                    |    |       |
| Al Mina                        | 129| (37.8)|
| Al Hali                        | 119| (34.9)|
| Al Hawak                       | 93 | (27.3)|
| Education status ***           |    |       |
| No formal education            | 50 | (14.7)|
| Primary education              | 75 | (22.0)|
| Secondary education or above   | 216| (63.3)|
| Employment status ****         |    |       |
| Unemployed                     | 142| (49.1)|
| Public service employee        | 51 | (17.7)|
| Private service employee       | 96 | (33.2)|
| Household size (members) **    |    |       |
| ≤4                             | 102| (35.5)|
| >4                             | 185| (64.5)|
| Axillary temperature (°C)      |    |       |
| Mean ± SD: 38.8 ± 0.7          |    |       |
| Headache                       | 325| (91.5)|
| Joint pain                     | 292| (82.3)|
| Chills                         | 235| (66.2)|
| Sweating                       | 232| (65.4)|
| Muscle pain                    | 102| (28.7)|
| Retro-orbital / ocular pain    | 96 | (27.0)|
| Vomiting                       | 72 | (20.3)|
| Skin rash                      | 3  | (0.8) |

* Total number of patients was 355
** a 3 missing cases; b 8 missing cases; c 14 missing or non-applicable cases; d 66 missing or non-applicable cases; e 68 missing cases; IQR, interquartile range.

https://doi.org/10.1371/journal.pone.0253556.t001
In contrast, vomiting (20.3%) and skin rash (0.8%) were the least frequent clinical features among febrile outpatients.

**Proportions of malaria and dengue mono- and co-infections**

Of 355 febrile patients, 32.4% had falciparum malaria as confirmed by microscopy and/or RDTs, where unmixed infection with *P. falciparum* was detected in 29.0% and 28.7% of patients by microscopy and RDTs, respectively. Microscopy revealed *P. vivax* in 3.1% of patients and mixed with *P. falciparum* in 1.1% of patients. On the other hand, 35.2% of patients were positive for dengue, where most cases were IgG-positive (13.0%) followed by those IgM/IgG-positive (9.6%) and NS1-positive (8.2%). Approximately two-thirds of dengue-positive patients had recent probable dengue, while 36.8% had past infections. Co-infection with falciparum malaria and recent probable dengue was detected among 4.8% of patients (Table 2).

**Comparison between co-infection and mono-infection with malaria and dengue in relation to sociodemographic and clinical characteristics**

Table 3 shows that there was no statistically significant difference between co-infection and mono-infection with malaria or dengue and the male gender, age of twenty years or older, having secondary education or above, being unemployed or living within households of more

| Infection status | n  | (%) |
|------------------|----|-----|
| **Microscopy-confirmed malaria** |    |     |
| *P. falciparum*   | 103| (29.0) |
| *P. vivax*        | 11 | (3.1)  |
| Co-infection with *P. falciparum* and *P. vivax* | 4 | (1.1) |
| **RDT-confirmed malaria** |    |     |
| *P. falciparum*   | 102| (28.7) |
| Non-falciparum species | 12 | (3.4) |
| Falciparum and non-falciparum species | 9 | (2.5) |
| **Total confirmed falciparum malaria (microscopy and/or RDT)** | 115| (32.4) |
| **Dengue RDT result** |    |     |
| IgM-positive      | 11 | (3.1) |
| IgG-positive      | 46 | (13.0) |
| IgM- and IgG-positive | 34 | (9.6) |
| NS1-positive      | 29 | (8.2) |
| NS1- and IgM- and/or IgG-positive | 5 | (1.4) |
| **Total confirmed dengue (RDT)** | 125| (35.2) |
| **Categories of RDT-confirmed dengue** |    |     |
| Recent probable (positive for IgM and/or NS1 irrespective of IgG) | 79 | (63.2) |
| Past (positive for IgG only) | 46 | (36.8) |
| **Malaria-dengue co-infection** | 17 | (4.8) |

* Total number of patients was 355; RDT, rapid diagnostic test; IgM, immunoglobulin M; IgG, immunoglobulin G; NS1, Non-structural protein 1; IQR, interquartile range

* Calculated from dengue-positive cases

* Calculated from dengue-positive cases

* Cases co-infected with falciparum malaria and recent probable dengue (because dengue was not diagnosed in patients with vivax malaria).
than four members. On the other hand, the odds of co-infection were significantly lower than the odds of malaria among patients presenting with sweating (OR = 0.1, 95% CI: 0.05–0.45; \(p < 0.001\)), while the odds of co-infection were 3.5 times significantly higher than the odds of dengue among patients presenting with vomiting (OR = 3.5, 95% CI: 1.20–10.04; \(p < 0.021\)). In contrast, there were no statistically significant differences between co-infection and mono-infection with either type among febrile patients concerning other studied clinical features.

**Discussion**

The proportions of mono-infection with falciparum malaria and dengue among febrile patients seeking healthcare in Hodeidah city were comparable, where each type of infection was diagnosed among about one-third of patients. Meanwhile, about two-thirds of dengue cases were recent probable infections, which is higher than that reported for acute dengue among about one-third of febrile patients with dengue-like illnesses in Hodeidah in 2012 using enzyme-linked immunosorbent assay (ELISA) and polymerase chain reaction (PCR) [19]. The high mono-infection proportions beside the high proportion of febrile cases negative for both types of infection underscore the necessity of laboratory confirmation and avoiding treatment of AFIs as being presumed malaria cases. Moreover, the emergence of other AFIs in the country, such as chikungunya [33], warrants further investigations and broadening the diagnostic panel used for passive case detection of AFIs.

Malaria and dengue co-existence was first reported among prisoners during a febrile outbreak in Hodeidah in mid-2018 [34] but without co-infection estimates. The present study unveiled a co-infection proportion of as low as almost 5%, indicating that malaria infections are more frequent among febrile patients having no dengue than dengue-infected ones. This finding is in line with a conclusion of a recent meta-analysis [35] that the odds of malaria are significantly lower in dengue-infected patients compared with non-infected ones. Such uncommon co-infection with malaria and dengue could be attributed to several factors, including different vectors and their habitats. Nevertheless, co-infection should not be ignored once one type of infection is diagnosed.
The co-infection proportion in the present study is lower than that (30.4%) recently reported among febrile patients from Hodeidah [36]. However, unlike the recruitment of outpatients resident in Hodeidah city for at least six months before the study, the latter study [36] recruited outpatients and inpatients from rural and urban areas, where 51.4% of co-infections were diagnosed among inpatients compared with 16.5% among outpatients. The role of using different dengue diagnostic techniques in the difference between the co-infection proportions among outpatients in the two studies could not be ruled out, where NS1 antigen and IgM/IgG antibodies were detected using RDTs in the present study whereas IgM/IgG antibodies were detected using ELISA in the previous study.

Malaria diagnosis in the present study using microscopy and antigen detection using RDTs may underestimate the proportion of falciparum malaria cases among febrile patients, which can lead to inadequate detection of malaria as a mono- or co-infection as shown by recently published literature [37–40]. Therefore, the findings of this study should be interpreted cautiously in this context, and the underestimation of malaria in mono- and co-infected febrile patients could not be ruled out. On the other hand, NS1 helps detect recent infections as early as one day from the onset of symptoms when combined with IgM and IgG antibodies for dengue diagnosis [30], allowing to cover all clinical stages of the disease. Although the diagnostic accuracy of RDTs to detect NS1 antigen is yet to be evaluated, the capacity of such RDTs to capture some PCR-negative cases at the end of the viremic phase has been evidenced among febrile patients [41]. Given that the RDT used in the present study might not be sensitive enough to enable the detection of all dengue infections, the large gap between the proportion of dengue mono-infection and malaria-dengue co-infection in a random sample of febrile patients could still be informative. RDTs are useful tools to screen for dengue in limited-resource countries with limited or unavailable reference diagnostic services [42], but it is recommended to use ELISA to confirm dengue diagnosis in suspected cases in such countries. However, IgM ELISAs can be less than 50% sensitive for confirming primary infection for at least 4 days due to the delayed increases in antibody titers [42]. Overall, the underestimation of mono- or co-infection with malaria and dengue among febrile patients in the present study could not be precluded. Such underestimation is not only due to the inadequacy of the detection methods used that have lower levels of sensitivity and specificity compared to molecular methods but also due to several other factors such as disease seasonality and the level of overlapping endemicity. Meanwhile, presumptive diagnosis of febrile cases by Yemeni physicians as dengue based on thrombocytopenia or malaria based on symptoms in a malaria-endemic area can lead to an overestimation of the proportion of either type of infection among patients with AFIs. This situation is typical of developing countries with limited diagnostic resources, where the actual incidence of infection with malaria and/or dengue is not correctly detected [14]. Therefore, the development of novel diagnostic tools, preferably as a single format, for both types of infection has been suggested [14].

Compared with malaria-dengue co-infection in Hodeidah and with the use of similar diagnostic tools, a higher proportion (7.2%; 27/367) was reported among febrile patients from Odisha state of India during a dengue outbreak in 2011 [23], but a lower proportion (0.2%; 3/1260) was reported among febrile patients from Sierra Leone in 2012–2013 [15]. The variations in co-infection proportions could be attributed to several factors, including the endemicity levels of the two diseases and the mobility patterns of populations in endemic countries. Unlike the present study, ELISA was the most frequently used method for the detection of dengue NS1, IgM and/or IgG followed by detecting the virus nucleic acid by PCR in other regions of the world [11–13, 16, 43–57]. Therefore, the differences in detection methods and study population categories make it inappropriate to compare the co-infection proportion among febrile patients from Hodeidah with those reported in these studies. Against this background,
higher co-infection with microscopy-confirmed malaria and ELISA-confirmed dengue was reported among 23.0% of dengue-positive febrile patients in Karachi, Pakistan in 2007–2008 [16], but lower proportions were reported from Punjab province of Pakistan (1.1% in 2003–2004 and 2.0% in 2012) for co-infection with microscopy-confirmed Plasmodium species and ELISA-confirmed dengue [13, 44]. Based on malaria microscopy and dengue ELISA, lower co-infection proportions (0.3–3.0%) were reported among febrile Indian patients from different Indian states between 2005 and 2014 [12, 48–50, 52, 55, 56], but higher co-infection proportions were reported among febrile patients from Mumbai during monsoons in 2014 and 2015, being 10.3% and 6.7%, respectively [54]. In Africa, malaria-dengue co-infection was reported among 2.0–6.0% of febrile Nigerian patients between 2008 and 2016 [43, 45, 53, 57], 3.0% (7/218) of Ghanaian patients with confirmed malaria [51] and 8.5% of febrile Tanzanian patients in 2013 [46]. In South America, however, lower co-infection proportions ranging from 1.0% (17/1723) to 2.8% (44/1578) were reported among febrile patients from French Guiana and the Brazilian Amazon [11, 47].

The present study revealed that sociodemographic characteristics could not be useful predictors to differentiate malaria-dengue co-infection from either type of mono-infection. Such finding is consistent with that reported among in-patients and out-patients in the city [36]. It is to be noted that gender bias might be introduced into the present study due to the recruitment of more males (63.0%), which should be considered in future studies to test the significance of difference between co-infection and mono-infection with malaria or dengue in relation to gender. Gender can be associated with differences in the likelihood of exposure to dengue vectors [58, 59].

Clinical features could not easily distinguish co-infection from either type of infection, where the quite similar clinical manifestations of malaria and dengue usually lead to ignoring the co-infection among febrile patients once a mono-infection with either type is confirmed. Yet, febrile patients presenting with sweating were significantly more likely to be infected with malaria than being co-infected, while those presenting with vomiting were significantly more likely to be co-infected than being infected with dengue. In another context, vomiting was found to be significantly more frequent among febrile patients co-infected with dengue and vivax malaria than those mono-infected with dengue in the Brazilian Amazon [47]. The absence of differences between co-infection and either type of mono-infection regarding other clinical features, such as joint pain and retro-orbital pain, makes it difficult to predict whether febrile patients confirmed with malaria might be co-infected with dengue and vice versa. Therefore, diagnosis of one type of infection should not exclude the presence of the other whose treatment could be ignored or, at least, delayed. In line with this, Abbasi et al. [16] and Mohapatra et al. [23] found a clinical similarity between malaria-dengue co-infection and dengue among Pakistani and Indian febrile patients, respectively. Because the present study was limited to outpatients not presenting with severe disease or complications due to the difficulty in accessing inpatients, the association of co-infection with disease severity needs to be investigated. In this context, more severe clinical presentations were found in co-infected patients admitted to hospitals compared with those mono-infected with either type of disease in French Guiana [22].

The outcomes of this study will contribute to informing healthcare personnel about malaria and dengue mono- and co-infection proportions among patients with AFIs in Hodeidah city. This is particularly important because treating febrile patients as presumed malaria cases is a common practice where diagnostic services are deficient or lacking, leading to unnecessary and irrational antimalarial treatment of AFIs other than malaria. On the other hand, confirming malaria or dengue mono-infection in co-infected patients may lead to ignoring the supportive treatment of dengue or treatment of malaria, respectively. Although no specific
medication for dengue currently exists, supportive treatment with antipyretics, analgesics and fluid replacement in case of dehydration is recommended and can be life-saving [60]. Another common practice by Yemeni physicians is using platelet count as an indicator of dengue among patients with AFIs wherever dengue diagnostics are not easily accessible or available. Despite being, among others, an indicator of dengue [61], thrombocytopenia can also be present in malaria [62, 63], necessitating its laboratory confirmation in febrile patients. At the public health level, the outcomes of the present study can help the National Malaria Control Programme (NMCP) in orienting its current case management recommendations. In this respect, the high proportion of dengue among febrile patients in Hodeidah can lead to their presumptive treatment as being malaria, confronting with the strategic component of malaria case management adopted by the NMCP that conforms to the WHO recommendation of universal diagnostic testing before malaria treatment [64, 65]. Therefore, educational and training interventions should be tailored and implemented by the NMCP to increase the adherence of public and private sector physicians to the national malaria treatment guidelines, including the treatment of confirmed rather than presumed malaria cases. Because the NMCP is the authority responsible for dengue control in the country, implementation of interventions for assessing the diagnostic accuracy of RDTs for dengue diagnosis and broadening the extent of their availability in malaria-endemic areas can help translate its national malaria treatment guidelines into practice.

Apart from studying mono- or co-infection with malaria and dengue among febrile patients, the potential co-infection with other AFIs with similar differential diagnosis but not investigated in the present study should be considered. This is evidenced by the finding that about one-third of febrile patients seeking healthcare in Hodeidah tested negative for both malaria and dengue. In this context, the emergence of a chikungunya outbreak was reported in Hodeidah city in 2011 [33] followed by reporting the co-circulation of chikungunya virus with DENV in the city in 2012 [19], raising the potential co-infection with other infectious causes of AFIs. Having the same vector and sharing similar symptoms with dengue, chikungunya should also be given priority when investigating AFIs in patients living in Hodeidah, preferably after assessing its burden as mono- and co-infection. In many malaria-endemic areas in low- and middle-income countries, AFIs other than malaria and dengue, such as chikungunya, leptospirosis and Q-fever, are usually neglected with the lack of a comprehensive, standardized and multi-center etiology research on the infectious causes of fever, even for severe cases [66]. Studies on non-malarial infectious causes of AFIs, either as mono- or co-infection with one or more circulating agents, are critically needed to raise the awareness of clinicians and disease control programmes about the local epidemiology and age distribution of the causes of AFIs as well as the burden of clinically indistinguishable febrile co-infections. A better understanding of the local epidemiology of malaria co-infections besides the non-malarial causes of AFIs using robust immunological and molecular techniques is critical for guiding the diagnostic approaches to AFIs and improving the outcomes of clinical management.

This study is limited by the fact that it was hospital-based recruiting symptomatic patients without severe infections due to difficulties in accessibility to inpatients. Therefore, its findings may not be generalizable and do not reflect the epidemiologic status of co-infection, neither among healthcare-seeking patients nor at the community level. However, the findings of the present study can be a basis for further large-scale hospital- and community-based studies in areas of the country co-endemic for both types of infection. Another limitation was introduced by the low co-infection proportion, which might make the study not powered enough to compare co-infection with malaria or dengue mono-infection in relation to clinical characteristics. Accordingly, more extensive studies should build on the findings of the present study to further assess such differences. On the other hand, it is recommended to assess the outcomes and
complications of malaria and dengue, as either mono- or co-infection, through longitudinal studies on sub-sets of patients.

Although dengue was diagnosed using RDTs, such types of tests also detect NS1 antigen as a useful marker of recent or acute dengue [29] together with IgM and IgG antibodies. However, the possible underestimation of dengue mono- or co-infection attributed to the nature of tests used in this study warrants further research adopting more robust immunological, such as IgM ELISA, and molecular techniques for dengue diagnosis together with the evaluation of the diagnostic accuracy of RDTs to broaden their accessibility and affordability as diagnostic tools in such a resource-limited country.

In conclusion, the proportions of mono-infection with malaria and dengue are comparable among about one-third of febrile outpatients in Hodeidah, while almost 5% of febrile cases can be co-infected. Sociodemographic characteristics and clinical features cannot easily distinguish malaria patients from dengue-infected or co-infected ones, reinforcing the necessity of proper laboratory diagnosis and avoidance of treating febrile patients as being presumed malaria cases in such a setting. Further large-scale studies are recommended to assess the burden of malaria and dengue, as mono- or co-infections, among febrile patients using more robust diagnostic tools in areas of the country co-endemic for both types of infection. Moreover, assessment of the epidemiologic burden of other infectious causes of AFI, particularly chikungunya, as a mono- or co-infection is warranted.

Supporting information

S1 Checklist. STROBE checklist.
(DOC)

S1 Table. Questionnaire (English & Arabic versions).
(DOCX)

S2 Table. Data set.
(XLS)

Acknowledgments

We thank the patients who agreed to participate in the study and the laboratory technicians who assisted while conducting the study. We also thank Dr. Adel Al-Jasari, Malaria and Vector Control Officer, WHO Country Office in Sana’a, Yemen for his critical comments and feedback during manuscript preparation. This research was conducted through the Structured Operational Research and Training Initiative (SORT IT), a global partnership led by the Special Program for Research and Training in Tropical Diseases at the World Health Organization (WHO/TDR). The model is based on a course developed jointly by the International Union against Tuberculosis and Lung Disease (The Union) and Médecins sans Frontières (MSF/Doctors Without Borders). The specific SORT IT program which resulted in this publication was jointly developed and implemented by: The Union Southeast Asia Office, New Delhi, India; the Centre for Operational Research, The Union, Paris, France; The Union, Mandalay, Myanmar; The Union, Harare, Zimbabwe; MSF Luxembourg Operational Research (LuxOR); MSF Operational Center Brussels (MSF OCB); Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Puducherry, India; Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India; All India Institute of Medical Sciences (AIIMS), New Delhi, India; ICMR - National Institute of Epidemiology, Chennai, India; Society for Education Welfare and Action (SEWA) – Rural, Jhagadia, India; Common Management Unit (AIDS, TB & Malaria), Ministry of National Health Services, Regulations and Coordination,
Islamabad, Pakistan; and Kidu Mobile Medical Unit, His Majesty's People's Project and Jigme Dorji Wangchuck National Referral Hospital, Thimphu, Bhutan.

Author Contributions

Conceptualization: Rashad Abdul-Ghani, Mohammed A. K. Mahdy.

Data curation: Rashad Abdul-Ghani, Mohammed A. K. Mahdy, Abdullah Alhariri.

Formal analysis: Rashad Abdul-Ghani.

Funding acquisition: Rashad Abdul-Ghani, Mohammed A. K. Mahdy.

Investigation: Sameer Alkubati.

Methodology: Rashad Abdul-Ghani, Sameer Alkubati.

Project administration: Sameer Alkubati, Abdullah A. Al-Mikhlafy.

Resources: Mrinalini Das, Kapilkumar Dave, Julita Gil-Cuesta.

Software: Mrinalini Das, Kapilkumar Dave, Julita Gil-Cuesta.

Supervision: Rashad Abdul-Ghani, Mohammed A. K. Mahdy, Sameer Alkubati, Abdullah A. Al-Mikhlafy, Abdullah Alhariri, Mrinalini Das, Kapilkumar Dave, Julita Gil-Cuesta.

Validation: Rashad Abdul-Ghani, Mrinalini Das, Kapilkumar Dave, Julita Gil-Cuesta.

Writing – original draft: Rashad Abdul-Ghani, Mrinalini Das, Kapilkumar Dave, Julita Gil-Cuesta.

Writing – review & editing: Rashad Abdul-Ghani, Mohammed A. K. Mahdy, Sameer Alkubati, Abdullah A. Al-Mikhlafy, Abdullah Alhariri, Mrinalini Das, Kapilkumar Dave, Julita Gil-Cuesta.

References

1. World Health Organization. World malaria report 2020: 20 years of global progress and challenges. Geneva: WHO; 2020. Available from: https://apps.who.int/iris/handle/10665/337660.

2. World Health Organization. Dengue guidelines for diagnosis, treatment, prevention and control: new edition. Geneva: WHO; 2009. Available from: https://apps.who.int/iris/handle/10665/44188.

3. World Health Organization. Global strategy for dengue prevention and control, 2012–2020: WHO report. Geneva: WHO; 2012.

4. World Health Organization. Dengue and severe dengue: key facts [cited 2019 11 Nov]. Available from: https://www.who.int/news-room/fact-sheets/detail/dengue-and-severe-dengue.

5. Salam N, Mustafa S, Hafiz A, Chaudhary AA, Deeba F, Parveen S. Global prevalence and distribution of coinfection of malaria, dengue and chikungunya: a systematic review. BMC Public Health. 2018; 18 (1):710. https://doi.org/10.1186/s12889-018-5626-z PMID: 29879935.

6. Wiwanitkit V. Concurrent malaria and dengue infection: a brief summary and comment. Asian Pac J Trop Biomed. 2011; 1(4):326–7. https://doi.org/10.1016/S2221-1691(11)60053-1 PMID: 23569785.

7. Yong LS, Koh KC. A case of mixed infections in a patient presenting with acute febrile illness in the tropics. Case Rep Infect Dis. 2013; 2013:562175. https://doi.org/10.1155/2013/562175 PMID: 23533853.

8. Katzelnick LC, Gresh L, Halloran ME, Mercado JC, Kuan G, Gordon A, et al. Antibody-dependent enhancement of severe dengue disease in humans. 2017; 368(8365):929–32. https://doi.org/10.1126/science.aan6836 PMID: 29097492.

9. Charrel RN, Brouqui P, Foucault C, de Lamballerie X. Concurrent dengue and malaria. Emerg Infect Dis. 2005; 11(7):1155–4. https://doi.org/10.3201/eid1107.041352 PMID: 16032797.

10. Ward DI. A case of fatal Plasmodium falciparum malaria complicated by acute dengue fever in East Timor. Am J Trop Med Hyg. 2006; 75(1):182–5. PMID: 16837729.
11. Carme B, Matheus S, Donutil G, Raulin O, Nacher M, Morvan J. Concurrent dengue and malaria in Cayenne Hospital, French Guiana. Emerg Infect Dis. 2009; 15(4):668–71. https://doi.org/10.3201/eid1504.080891 PMID: 19331769.

12. Hati AK, Bhattacharjee I, Mukherjee H, Bandopadhyay B, Bandopadhyay D, De R, et al. Concurrent dengue and malaria in an area in Kolkata. Asian Pac J Trop Med. 2012; 5(4):315–7. https://doi.org/10.1016/S1995-7645(12)60046-7 PMID: 2249525.

13. Assir MZ, Masood MA, Ahmad HI. Concurrent dengue and malaria infection in Lahore, Pakistan during the 2012 dengue outbreak. Int J Infect Dis. 2014; 18:41–6. https://doi.org/10.1016/j.ijid.2013.09.007 PMID: 24183717.

14. Selvaretnam AAP, Sahu PS, Sahu M, Ambu S. A review of concurrent infections of malaria and dengue in Asia. Asian Pac J Trop Biomed. 2016; 6(7):633–8. https://doi.org/10.1016/S2221-1691(13)60087-8 PMID: 2249525.

15. Dariano DF, Taitt CR, Jacobson KH, Bangura U, Bockarie AS, Bockarie MJ, et al. Surveillance of vector-borne infections (chikungunya, dengue, and malaria) in Bo, Sierra Leone, 2012–2013. Am J Trop Med Hyg. 2017; 97(4):1151–4. https://doi.org/10.4269/ajtmh.16-0798 PMID: 29031286.

16. Abbasi A, Butt N, Sheikh QH, Bhutto AR, Munir SM, Ahmed SM. Clinical features, diagnostic techniques and management of dual dengue and malaria infection. J Coll Physicians Surg Pak. 2009; 19(1):25–9. https://doi.org/01.2009/JCPSP.2529 PMID: 19149976.

17. Bin Ghouth AS, Amarasinha A, Letson GW. Dengue outbreak in Hadramout, Yemen, 2010: an epidemiological perspective. Am J Trop Med Hyg. 2012; 86(6):1072–6. https://doi.org/10.4269/ajtmh.2012.11-0723 PMID: 22666521.

18. Madani TA, Abuelzein el TM, Al-Bar HM, Azhar EI, Kao M, Alshoeb HO, et al. Outbreak of viral hemorrhagic fever caused by dengue virus type 3 in Al-Mukalla, Yemen. BMC Infect Dis. 2013; 13:136. https://doi.org/10.1186/1471-2334-13-136 PMID: 23497142.

19. Rezza G, El-Sawaf G, Faggioni G, Vescio F, Al Ameri R, De Santis R, et al. Co-circulation of dengue and chikungunya viruses, Al Hudaydah, Yemen, 2012. Emerg Infect Dis. 2014; 20(8):1351–4. https://doi.org/10.3201/eid2008.131615 PMID: 25061762.

20. WHO Regional Office for the Eastern Mediterranean. WHO health emergencies: WHO scales up response to control dengue fever in Yemen Geneva: WHO; 2016 [cited 2019 Feb. 12]. Available from: http://www.emro.who.int/eha/news/who-scales-up-response-to-control-dengue-fever-in-yemen.html.

21. World Health Organization. Yemen Health Cluster. health cluster bulletin November-December [cited 2019 12 Feb]. Available from: https://www.who.int/health-cluster/countries/yemen/Yemen-Health-Cluster-Bulletin-November-December-2018.pdf.

22. Epelboin L, Hanf M, Dussart P, Ouar-Epelboin S, Djossou F, Nacher M, et al. Is dengue and malaria co-infection more severe than single infections? A retrospective matched-pair study in French Guiana. Malar J. 2012; 11:142. https://doi.org/10.1186/1475-2875-11-142 PMID: 22549018.

23. Mohapatra MK, Patra P, Agrawala R. Manifestation and outcome of concurrent malaria and dengue infection. J Vector Borne Dis. 2012; 49(4):262–5. PMID: 23428528.

24. Alam A, Dm M. A case of cerebral malaria and dengue concurrent infection. Asian Pac J Trop Biomed. 2013; 3(5):416–7. https://doi.org/10.1016/S2221-1691(13)60087-8 PMID: 23646308.

25. Chong SE, Mohamad Zaini RH, Suraiya S, Lee KT, Lim JA. The dangers of accepting a single diagnosis: case report of concurrent Plasmodium knowlesi malaria and dengue infection. Malar J. 2017; 16(1):2. https://doi.org/10.1186/s12936-016-1666-y PMID: 28049485.

26. Bioland PB. Drug resistance in malaria. Geneva: World Health Organization; 2001.

27. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandebroucke JP, et al. Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ. 2007; 335(7624):806–8. https://doi.org/10.1136/bmj.39335.541782.AD PMID: 17947786.

28. Central Statistical Organization. Statistical Year Book for 2017. Available from: http://www.cso-yemen.com/content.php?lng=english&id=690.

29. World Health Organization. In vitro diagnostics and laboratory technology: WHO list of prequalified in vitro diagnostic products 2018. Available from: https://www.who.int/diagnostics_laboratory/evaluations/201013_prequalified_product_list.pdf?ua=1.

30. Centers for Disease Prevention and Control. Dengue: laboratory guidance and diagnostic testing [cited 2019 12 Nov]. Available from: https://www.cdc.gov/dengue/clinicallab/laboratory.html.

31. Cheesbrough M. District Laboratory Practice in Tropical Countries: Part 1. London: Oxford University Press; 2010.

32. World Health Organization. Basic Malaria Microscopy. Part 1. Learner’s Guide. 2nd ed. Geneva: WHO; 2010. Available from: https://apps.who.int/iris/handle/10665/44208.
33. Malik MR, Mnzava A, Mohareb E, Zayed A, Al Kohlani A, Thabet AA, et al. Chikungunya outbreak in Al-Hudaydah, Yemen, 2011: epidemiological characterization and key lessons learned for early detection and control. J Epidemiol Glob Health. 2014; 4(3):203–11. https://doi.org/10.1016/j.jegh.2014.01.004 PMID: 25107656.

34. International Organization for Migration. IOM Yemen: weekly situation report 20–26 May 2018. Available from: https://displacement.iom.int/system/tdf/reports/IOM%20Yemen%20-%20Sitrep%20-%202020-26%20May%202018.pdf?file=1&type=node&id=3712.

35. Kotepui M, Kotepui KU. Prevalence and laboratory analysis of malaria and dengue co-infection: a systematic review and meta-analysis. BMC Public Health. 2019; 19(1):1148. https://doi.org/10.1186/s12889-019-7488-4 PMID: 31522680.

36. Al-Areeq I, Alghalibi S, Yusuf Q, Al-Masrafi I, Al-Kamarany MA. Epidemiological characteristics of malaria coinfection with dengue fever in Hodeidah, Yemen. Int J Trop Med Health. 2020; 40(3):1–10.

37. Berhane A, Anderson K, Mihreteab S, Gresty K, Rogier E, Mohamed S, et al. Major threat to malaria control programs by Plasmodium falciparum lacking histidine-rich protein 2, Eritrea. Emerg Infect Dis. 2018; 24(3):462–70. https://doi.org/10.3201/eid2403.171723 PMID: 29460730.

38. Watson OJ, Sumner KM, Janko M, Goel V, Winskill P, Slater HC, et al. False-negative malaria rapid diagnostic test results and their impact on community-based malaria surveys in sub-Saharan Africa. BMJ Glob Health. 2019; 4(4):e001582. https://doi.org/10.1136/bmjgh-2019-001582 PMID: 31406591.

39. Kaur C, Pramanik A, Kumar K, Mandage R, Dinda AK, Sankar J, et al. Renal detection of Plasmodium falciparum and Plasmodium knowlesi in malaria associated acute kidney injury: a retrospective case-control study. BMC Res Notes. 2020; 13(1):37. https://doi.org/10.1186/s13104-020-4900-1 PMID: 31959229.

40. Mandage R, Kaur C, Pramanik A, Kumar V, Kodan P, Singh A, et al. Association of dengue virus and Leptospira co-infections with malaria severity. Emerg Infect Dis. 2020; 26(8):1645–53. https://doi.org/10.3201/eid2608.191214 PMID: 32687019.

41. Huits R, Soentjens P, Maniewski-Keiner U, Theunissen C, Van Den Broucke S, Florence E, et al. Clinical utility of the nonstructural 1 antigen rapid diagnostic test in the management of dengue in returning travelers with fever. Open Forum Infect Dis. 2017; 4(1):ofw273. https://doi.org/10.1093/ofid/ofw273 PMID: 28482625.

42. Hunspurger EA, Sharp TM, Lalita P, Tikomaidruba K, Cardoso YR, Naivalu T, et al. Use of a rapid test for diagnosis of dengue during suspected dengue outbreaks in resource-limited regions. J Clin Microbiol. 2016; 54(8):2090–5. https://doi.org/10.1128/JCM.00521-16 PMID: 27225409.

43. Baba M, Logue CH, Oderinde B, Abdulmaleek H, Williams J, Lewis J, et al. Evidence of arbovirus co-infection in suspected febrile malaria and typhoid patients in Nigeria. J Infect Dev Ctries. 2013; 7(1):51–9. https://doi.org/10.3855/jidct.2411 PMID: 23924921.

44. Ali N, Nadeem A, Anwar M, Tariq WU, Chotani RA. Dengue fever in malaria endemic areas. J Coll Physicians Surg Pak. 2006; 16(5):340–2. https://doi.org/5.2006/JCPSP.340 https://doi.org/10.1016/j.virusres.2014.07.023 PMID: 25078778.

45. Oyero OG, Ayukekong JA. High dengue NS1 antigenemia in febrile patients in Ibadan, Nigeria. Virus Res. 2014; 191:59–61. https://doi.org/10.1016/j.virusres.2014.07.023 PMID: 25078778.

46. Chipwaza B, Mugas J, Selamani M, Amuri M, Mosha F, Ngatunga SD, et al. Dengue and chikungunya fever among viral diseases in outpatient febrile children in Kilosa district hospital, Tanzania. PLoS Negl Trop Dis. 2014; 8(11):e3335. https://doi.org/10.1371/journal.pntd.0003335 PMID: 25412076.

47. Magalhaes BM, Siqueira AM, Alexandre MA, Souza MS, Gimaquid JB, Bastos MS, et al. P. vivax malaria and dengue fever co-infection: a cross-sectional study in the Brazilian Amazon. PLoS Negl Trop Dis. 2014; 8(10):e3239. https://doi.org/10.1371/journal.pntd.0003239 PMID: 25340346.

48. Singh R, Singh SP, Ahmad N. A Study of etiological pattern in an epidemic of acute febrile illness during monsoon in a tertiary health care institute of Uttarakhanda, India. J Clin Diagn Res. 2014; 8(6):MC01–3. https://doi.org/10.7860/JCDR/2014/8965.4435 PMID: 25121013.

49. Mittal G, Ahmad S, Agarwal RK, Dhar M, Mittal M, Sharma S. Aetiology of acute undifferentiated febrile illness in adult patients—an experience from a tertiary care hospital in northern India. J Clin Diagn Res. 2015; 9(12):DC22–4. https://doi.org/10.3760/JCDR/2015/11168.6990 PMID: 26816892.

50. Singla N, Arora S, Goel P, Chander J, Huria A. Dengue in pregnancy: an under-reported illness, with special reference to other existing co-infections. Asian Pac J Trop Med. 2015; 8(3):206–8. https://doi.org/10.1016/S1995-7645(14)60316-3 PMID: 25902162.

51. Stoler J, Dellimini RK, Bonney JH, Oduro AR, Owusu-Agyei S, Fobil JN, et al. Evidence of recent dengue exposure among malaria parasite-positive children in three urban centers in Ghana. Am J Trop Med Hyg. 2015; 92(3):497–500. https://doi.org/10.4269/ajtmh.14-0678 PMID: 25582693.

52. Ahmad S, Dhar M, Mittal G, Bhat NK, Shirazi N, Kalra V, et al. A comparative hospital-based observational study of mono- and co-infections of malaria, dengue virus and scrub typhus causing acute
undifferentiated fever. Eur J Clin Microbiol Infect Dis. 2016; 35(4):705–11. https://doi.org/10.1007/s10096-016-2590-3 PMID: 26851948.

53. Ayorinde AF, Oyeyiga AM, Nosegbe NO, Folarin OA. A survey of malaria and some arboviral infections among suspected febrile patients visiting a health centre in Simawa, Ogun State, Nigeria. J Infect Public Health. 2016; 9(1):52–9. https://doi.org/10.1016/j.jiph.2015.06.009 PMID: 26256113.

54. Barua A, Yeolekar M. Concurrent dengue and malaria coinfection: observations from a central Mumbai hospital. Int J Infect Dis. 2016; 45:165.

55. Raja JM, Mary A, Usha S. A study on dual infections in pyrexia cases. Int J Med Res Health Sci. 2016; 5.

56. Rao MR, Padhy RN, Das MK. Prevalence of dengue viral and malaria parasitic co-infections in an epidemic district, Angul of Odisha, India: An eco-epidemiological and cross-sectional study for the prospective aspects of public health. J Infect Public Health. 2016; 9(4):421–8. https://doi.org/10.1016/j.jiph.2015.10.019 PMID: 26653975.

57. Kolawole OM, Seriki AA, Irekeola AA, Bello KE, Adeyemi OO. Dengue virus and malaria concurrent infection among febrile subjects within Ilorin metropolis, Nigeria. J Med Virol. 2017; 89(8):1347–53. https://doi.org/10.1002/jmv.24788 PMID: 28198544.

58. Anker M, Arima Y. Male-female differences in the number of reported incident dengue fever cases in six Asian countries. Western Pac Surveill Response J. 2011; 2(2):17–23. https://doi.org/10.5365/WPSAR.2011.2.1.002 PMID: 23908884.

59. Prasith N, Keosavanh O, Phengxay M, Stone S, Lewis HC, Tsuyuoka R, et al. Assessment of gender distribution in dengue surveillance data, the Lao People’s Democratic Republic. Western Pac Surveill Response J. 2013; 4(2):17–24. https://doi.org/10.5365/WPSAR.2012.3.4.020 PMID: 24015367.

60. Rajapakse S, Rodrigo C, Rajapakse A. Treatment of dengue fever. Infect Drug Resist. 2012; 5:103–12. https://doi.org/10.2147/IDR.S22613 PMID: 22870039.

61. Ahmed S, Ali N, Ashraf S, Ilyas M, Tariq WU, Chotani RA. Dengue fever outbreak: a clinical management experience. J Coll Physicians Surg Pak. 2008; 18(1):8–12. https://doi.org/01.2008/JCPSP.0812 PMID: 18452660.

62. Carme B, Sobesky M, Biard MH, Cotellon P, Aznar C, Fontanella JM. Non-specific alert system for dengue epidemic outbreaks in areas of endemic malaria. A hospital-based evaluation in Cayenne (French Guiana). Epidemiol Infect. 2003; 130(1):93–100. https://doi.org/10.1017/s0950268802007641 PMID: 12613750.

63. Khan SJ, Abbass Y, Marwat MA. Thrombocytopenia as an indicator of malaria in adult population. Malar Res Treat. 2012; 2012:405981. https://doi.org/10.1155/2012/405981 PMID: 22811952

64. World Health Organization. Guidelines for the treatment of malaria. 2nd ed. Geneva: WHO; 2010.

65. World Health Organization. Test, treat, track: scaling up diagnostic testing, treatment and surveillance for malaria. Geneva: Global Malaria Programme/ WHO; 2012. Available from: https://apps.who.int/iris/handle/10665/337979.

66. Prasad N, Murdoch DR, Reyburn H, Crump JA. Etiology of severe febrile illness in low- and middle-income countries: a systematic review. PLoS One. 2015; 10(6):e0127962. https://doi.org/10.1371/journal.pone.0127962 PMID: 26126200.